The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Alizapride
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
A03FA05
CAS registry number (Chemical Abstracts Service)
0059338-93-1
Chemical Formula
C16-H21-N5-O2
Molecular Weight
315
Therapeutic Categories
Antiemetic agent
Dopamine agonist
Chemical Name
N-[(1-Allyl-2-pyrrolidinyl)metyl]-6-metoxy-1H-benzotriazole-5-carboxamide (WHO)
Foreign Names
- Alizapridum (Latin)
- Alizaprid (German)
- Alizapride (French)
- Alizaprida (Spanish)
Generic Name
- Alizapride (OS: DCIT, DCF)
Brand Names
- Alizaprida Humax
Humax, Colombia - Nausilex
Minapharm, Egypt - Limican
Pharmafar, Italy - Litican
Sanofi Belgium, Belgium - Litican 50mg
Sanofi Belgium, Luxembourg - Litican 50mg/2ml
Sanofi Belgium, Luxembourg - Plitican
Sanofi-Aventis, Colombia; Sanofi-Aventis, France; Sanofi-Aventis, Kuwait - Plitivan
Sanofi-Aventis, Colombia - Superan
Sanofi-Aventis Farmaceutica, Brazil - Vergentan
Sanofi-Aventis Deutschland, Germany
Glossary
| Term | Definition |
|---|---|
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
